Brimonidine for Rosacea: Redness Relief and Rebound

What counted as improvement?

Two Galderma-sponsored trials randomized 553 adults, mostly White women with moderate-to-severe persistent redness. Success required two-grade improvement in both patient and clinician ratings at hours 3, 6, 9 and 12 on day 29. At hour 12, rates were 22.5% versus 8.9% and 21.5% versus 9.7% for brimonidine versus inactive gel. These are averages across five datasets estimating missing observations, using all randomized participants. Both trials favored treatment statistically. Fewer than three inflammatory lesions were required, limiting conclusions about bumps. Investigator financial ties were disclosed.¹

Can redness return worse?

One participant stopped on day 11 after intermittent rebound. Assessments two and four weeks after treatment could miss earlier worsening.¹

The current US label explicitly warns that redness can return worse than baseline. Mirvaso 0.33% treats persistent rosacea redness in adults; it is not an eye medicine. Avoid irritated skin and open wounds. Discuss cardiovascular disease, blood-pressure medicines, pregnancy and breastfeeding before use. Keep it away from children. Stop use and seek emergency help for throat tightening or tongue swelling.²

What should I record?

Dermatologists describe the color-fading effect as temporary, often strongest three to six hours after application. Their care plans also include gentle cleansing, moisturizer and sunscreen. Ask your prescriber how to respond if redness worsens, rather than applying extra gel.³

In Skin, Head to Toe, “Describe Your Own Face” and “Triggers and What Helps” organize notes on color, warmth, stinging and exposures. Add application times and when symptoms return to those notes for your appointment.